Search
Panobacumab
go.drugbank.com/drugs/DB15342InvestigationalPanobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigational[L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Linvoseltamab
go.drugbank.com/drugs/DB17447ApprovedInvestigational[L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the
ETBX-011
go.drugbank.com/drugs/DB17464InvestigationalETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]
Teriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigational[A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]
PTI-801
go.drugbank.com/drugs/DB05300InvestigationalIt is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
MB-102 CD123 CAR
go.drugbank.com/drugs/DB17366InvestigationalMB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.